Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 28 articles:
HTML format



Single Articles


    October 2025
  1. EL BABA R, Haidar Ahmad S, Vanhulle C, Vreux L, et al
    Formation of polyploid giant cancer cells and the transformative role of human cytomegalovirus IE1 protein.
    Cancer Lett. 2025;630:217824.
    PubMed     Abstract available


    July 2025
  2. LI J, Shi J, Ding J, Qu W, et al
    Metabolic gatekeeper ACAD9 coordinates linoleic acid metabolism and redox homeostasis via mitochondrial complex I to drive ovarian cancer progression.
    Cancer Lett. 2025;630:217903.
    PubMed     Abstract available


  3. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
    Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].
    Cancer Lett. 2025 Jul 2:217889. doi: 10.1016/j.canlet.2025.217889.
    PubMed    


    April 2025
  4. DURAKI D, Jabeen M, Mao C, Wang L, et al
    A Necrosis Inducer Promotes an Immunogenic Response and Destroys Ovarian Cancers in Mouse Xenografts and Patient Ascites Organoids.
    Cancer Lett. 2025 Apr 29:217738. doi: 10.1016/j.canlet.2025.217738.
    PubMed     Abstract available


    March 2025
  5. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    PubMed     Abstract available


    February 2025
  6. WANG Q, Liu W, Fan Y, Liu S, et al
    Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.
    Cancer Lett. 2025 Feb 25:217588. doi: 10.1016/j.canlet.2025.217588.
    PubMed    


  7. TAMURA T, Nagai S, Masuda K, Imaeda K, et al
    mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer.
    Cancer Lett. 2025 Feb 17:217565. doi: 10.1016/j.canlet.2025.217565.
    PubMed     Abstract available


    December 2024
  8. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
    N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
    Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
    PubMed     Abstract available


    November 2024
  9. FIELD NR, Dickson KA, Nassif NT, Marsh DJ, et al
    SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
    Cancer Lett. 2024;605:217282.
    PubMed     Abstract available


  10. BHOWMIK AD, Shaw P, Gopinatha Pillai MS, Rao G, et al
    Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.
    Cancer Lett. 2024 Nov 28:217357. doi: 10.1016/j.canlet.2024.217357.
    PubMed     Abstract available


    September 2024
  11. LEWIS F, Beirne J, Henderson B, Norris L, et al
    Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
    Cancer Lett. 2024 Sep 26:217279. doi: 10.1016/j.canlet.2024.217279.
    PubMed     Abstract available


    August 2024
  12. WU H, Sun C, Cao W, Teng Q, et al
    Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Cancer Lett. 2024;602:217192.
    PubMed     Abstract available


    July 2024
  13. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
    The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
    Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
    PubMed     Abstract available


  14. XU J, Lu W, Wei X, Zhang B, et al
    Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Cancer Lett. 2024;593:216928.
    PubMed     Abstract available


    June 2024
  15. FENG X, Ji Z, Fan X, Kong Y, et al
    ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
    Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
    PubMed     Abstract available


  16. MENG H, Miao H, Zhang Y, Chen T, et al
    YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
    Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
    PubMed     Abstract available


  17. YU Y, Lyu C, Li X, Yang L, et al
    Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Cancer Lett. 2024;596:217022.
    PubMed     Abstract available


    April 2024
  18. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    PubMed     Abstract available


  19. KAUR P, Shankar E, Gupta S
    EZH2-mediated development of therapeutic resistance in cancer.
    Cancer Lett. 2024;586:216706.
    PubMed     Abstract available


    March 2024
  20. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
    Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
    Cancer Lett. 2024;585:216673.
    PubMed     Abstract available


    February 2024
  21. LIU J, Liu C, Ma Y, Pan X, et al
    STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).
    Cancer Lett. 2024 Feb 17:216700. doi: 10.1016/j.canlet.2024.216700.
    PubMed     Abstract available


    November 2023
  22. GARG V, Kumar L
    Metronomic chemotherapy in ovarian cancer.
    Cancer Lett. 2023 Nov 1:216469. doi: 10.1016/j.canlet.2023.216469.
    PubMed     Abstract available


    October 2023
  23. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
    Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
    Cancer Lett. 2023 Oct 12:216437. doi: 10.1016/j.canlet.2023.216437.
    PubMed     Abstract available


    September 2023
  24. VENKATA PP, Jayamohan S, He Y, Alejo S, et al
    Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
    Cancer Lett. 2023 Sep 13:216383. doi: 10.1016/j.canlet.2023.216383.
    PubMed     Abstract available


    August 2023
  25. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    PubMed     Abstract available


    July 2023
  26. CHEN X, Zhou J, Li X, Wang X, et al
    Corrigendum to "Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype" [Cancer Lett. 435 (28 October 2018) 80-91].
    Cancer Lett. 2023 Jul 8:216292. doi: 10.1016/j.canlet.2023.216292.
    PubMed    


    May 2023
  27. SHAO Y, Li H, Wu Y, Wang X, et al
    The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer.
    Cancer Lett. 2023;565:216241.
    PubMed     Abstract available


    April 2023
  28. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
    Cancer Lett. 2023;563:216196.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.